# Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia

> **NCT00315484** · PHASE4 · COMPLETED · sponsor: **Ortho Biotech Products, L.P.** · enrollment: 358 (actual)

## Conditions studied

- Anemia
- Chemotherapy

## Interventions

- **DRUG:** Epoetin alfa and Darbepoetin alfa

## Key facts

- **NCT ID:** NCT00315484
- **Lead sponsor:** Ortho Biotech Products, L.P.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 358 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00315484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00315484, "Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00315484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*